The combination of two HER2-targeting drugs – Seagen's oral Tukysa and Roche's intravenous antibody-drug conjugate (ADC) Kadcyla – has shown a benefit over Kadcyla alone a
AstraZeneca and Daiichi Sankyo have claimed approval in the EU for Enhertu as a second-line therapy for HER2-positive metastatic breast cancer, moving the drug up the treatment pathway.
NICE has decided not to recommend Seagen's orally-active HER2 inhibitor Tukysa for advanced breast cancer in draft guidance, saying it isn't a cost-effective use of NHS resources.<
The FDA has approved Seattle Genetics' breast cancer drug Tukysa (tucatinib) four months early, including in certain patients whose disease has spread to the brain.
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.